Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.58 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075760 | 0.94 | APOBEC3A (0.68) | POLBATMLMNASMN1; SMN2USP2 | |
| SCHEMBL959386 | 0.84 | USP2 (0.68) | POLBLMNASMN1; SMN2USP2TSHR | |
| SCHEMBL289460 | 0.84 | USP2 (0.62) | POLBLMNASMN1; SMN2USP2TSHR | |
| SCHEMBL1742543 | 0.83 | USP2 (0.71) | POLBLMNASMN1; SMN2USP2KMT2A | |
| SCHEMBL2074764 | 0.83 | POLB (0.62) | POLBLMNATSHRHTTALDH1A1 | |
| SCHEMBL6034889 | 0.83 | KMT2A (0.59) | LMNASMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL21813105 | 0.83 | POLB (0.61) | POLBLMNASMN1; SMN2TSHRKMT2A | |
| SCHEMBL7106543 | 0.81 | ATM (0.69) | POLBATMLMNASMN1; SMN2USP2 | |
| SCHEMBL3936569 | 0.80 | POLB (1.00) | POLBATMLMNASMN1; SMN2USP2 | |
| SCHEMBL4006404 | 0.80 | L3MBTL1 (0.58) | LMNASMN1; SMN2USP2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575942-B1 | COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | EP | claimed |
| US-20060173014-A1 | Nobel compounds having selective inhibiting effect at gsk3 | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | claimed |
| US-20060116385-A1 | Novel compounds having selective inhibiting effect at gsk3 | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | claimed |
| JP-2006512337-A | — | — | 2006-04-13 | — | — | JP | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1575942-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| EP-1575939-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| WO-2004055009-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | claimed |
| WO-2004055006-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-12496302-B2 | Compositions and methods for the treatment and diagnosis of cancer | THE GENERAL HOSPITAL CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | BIOVENTURES, LLC | 2024-02-29 | — | — | US | disclosed |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | BIOVENTURES, LLC | 2024-02-29 | — | — | US | disclosed |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | BIOVENTURES, LLC | 2024-02-29 | — | — | US | disclosed |
| EP-1575942-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004055009-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004055006-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496302-B2 | Compositions and methods for the treatment and diagnosis of cancer | NSUN2, RNMT, TRDMT1 | POLB 38/4885ATM 629/4885LMNA 1148/4885 |
| US-20060173014-A1 | Nobel compounds having selective inhibiting effect at gsk3 | GSK3B, GSK3A, GSKIP | POLB 2373/4885ATM 494/4885LMNA 1480/4885 |
| US-20060116385-A1 | Novel compounds having selective inhibiting effect at gsk3 | GSK3B, GSK3A, NR5A2 | POLB 3741/4885ATM 3711/4885LMNA 2154/4885 |
| US-20240066033-A1 | Compositions and Methods for the Treatment and Diagnosis of Cancer | NSUN2, RNMT, TRDMT1 | POLB 38/4885ATM 629/4885LMNA 1148/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | POLB 2675/4885ATM 1066/4885LMNA 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.